{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 10 of 10 results
Status:
Investigational
Source:
INN:linoserpaturev [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:teserpaturev [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04047732: Phase 1/Phase 2 Interventional Unknown status TGM-1 Related Autosomal Recessive Congenital Ichthyosis
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04348916: Phase 1 Interventional Terminated Cancer
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:vusolimogene oderparepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03252808: Phase 1 Interventional Active, not recruiting Pancreatic Cancer Stage III
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01721018: Phase 1/Phase 2 Interventional Completed Malignant Pleural Mesothelioma
(2012)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125774
(2023)
Source URL:
First approved in 2023
Source:
BLA125774
Source URL:
Class:
STRUCTURALLY DIVERSE